2021 World Conference on Lung Cancer (Posters)-FP12. The Intrinsic Limitation and Clinical Impact of Mutant Allele-Specific Real-Time PCR-Based EGFR Mutation Assay in NSCLC

FP12. The Intrinsic Limitation and Clinical Impact of Mutant Allele-Specific Real-Time PCR-Based EGFR Mutation Assay in NSCLC

Back to course

Video Transcription

Video Summary

Dr. Jiayi Shen from Taipei Veterans General Hospital discusses the limitations of the COBAS EGFR mutation test, a commonly used assay in non-small-cell lung cancer. The test has an intrinsic detection limitation due to its primer designs, resulting in a false negative rate of 8.1%. In a retrospective cohort study, using next-generation sequencing (NGS), it was found that the false negative rate of the COBAS test increased to 11.3%. The study also identified other druggable driver mutations, such as ROS1, BRAF, and met exome 14 skipping, in 64.5% of patients. The findings highlight the importance of comprehensive molecular analysis in determining treatment strategies and improving clinical outcomes.

Asset Subtitle

Chia-I Shen

Meta Tag

Speaker Chia-I Shen

Topic Predictive Tumor Based Assays/ Biomarkers/ Pathology

Keywords

COBAS EGFR mutation test

limitations

false negative rate

next-generation sequencing

druggable driver mutations